BCATc Inhibitor 2 - ≥99% , CAS No.406191-34-2
Disponible
SKU
B648527
BCATc Inhibitor 2 is a selective branched-chain aminotransferase (BCAT) inhibitor for research of neurodegenerative diseases. The IC 50 s of 0.2 μM, 0.8 μM and 3.0 μM for rat cytosolic isoenzyme rBCATc, human cytosolic isoenzyme hBCATc and rat mitochondrial isoenzyme rBCATm, respectively. BCATc, also called BCAT1, is in the cytoplasm
In Vitro
BCATc Inhibitor 2 decreases calcium influx in neuronal cultures with an IC 50 =4.8±1.2 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BCATc Inhibitor 2 also blocks calcium influx into neuronal cells following inhibition of glutamate uptake, and demonstrates neuroprotective efficacy in vivo . ?\nFollowing a 30 mg/kg subcutaneous injection to Lewis rats, BCATc Inhibitor 2 reaches a peak plasma concentration (Cmax) of 8.28 μg/mL at 0.5 h (t max ).? The mean plasma exposure (AUC) value is 19.9 μg h/mL, and the mean terminal half-life ranged from 12 to 15 h, indicating favorable PK parameters of BCATc Inhibitor 2 . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:IC50: 0.2 μM (rBCATc), 0.8 μM (hBCATc), 3.0 μM (rBCATm)
Más Información
| CAS | 406191-34-2 |
|---|---|
| Especificaciones y pureza | ≥99% |
| Condiciones de almacenamiento de almacenamiento | Protected from light,Store at -80°C |
| Enviado en | Dry ice packs + Cold packs |
| Product Description | BCATc Inhibitor 2 is a selective branched-chain aminotransferase (BCAT) inhibitor for research of neurodegenerative diseases. The IC 50 s of 0.2 μM, 0.8 μM and 3.0 μM for rat cytosolic isoenzyme rBCATc, human cytosolic isoenzyme hBCATc and rat mitochondrial isoenzyme rBCATm, respectively. BCATc, also called BCAT1, is in the cytoplasm In Vitro BCATc Inhibitor 2 decreases calcium influx in neuronal cultures with an IC 50 =4.8±1.2 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BCATc Inhibitor 2 also blocks calcium influx into neuronal cells following inhibition of glutamate uptake, and demonstrates neuroprotective efficacy in vivo . ?\nFollowing a 30 mg/kg subcutaneous injection to Lewis rats, BCATc Inhibitor 2 reaches a peak plasma concentration (Cmax) of 8.28 μg/mL at 0.5 h (t max ).? The mean plasma exposure (AUC) value is 19.9 μg h/mL, and the mean terminal half-life ranged from 12 to 15 h, indicating favorable PK parameters of BCATc Inhibitor 2 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.2 μM (rBCATc), 0.8 μM (hBCATc), 3.0 μM (rBCATm) |
| Solubilidad | DMSO : 250 mg/mL (596.99 mM; Need ultrasonic) |
Reseñas
Reseñas de cliente
Remind me later